Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CONTRAIL I trial of iscalimab versus tacrolimus-based standard of care in de novo adult liver transplant recipients
2018-001836-24Phase 2Terminated
- Sponsor
- Novartis
- Start
- Feb 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of iscalimab in Hepatic transplant rejection (LTR) (3 arms), sponsored by Novartis. Primary endpoint: Incidence of composite efficacy failure at Month 12. Started Feb 2019; status: terminated.
02
Drugs
iscalimab
03
Conditions
Hepatic transplant rejection (LTR)
Beyond the preview
Go deeper on 2018-001836-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001836-24.